Loxapine
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Using no additional skill here — this is a direct content-generation task per the explicit report template already provided in the prompt.
Loxapine: From Schizophrenia to Acute Agitation in Bipolar Disorder
One-Sentence Summary
Loxapine is a first-generation (typical) antipsychotic of the dibenzoxazepine class, historically used to treat schizophrenia via oral administration for decades. The TxGNN model predicts it may be effective for manic bipolar affective disorder (specifically, acute agitation associated with bipolar mania), with 0 registered clinical trials in the evidence pack's trial registry but 20 supporting publications, including completed Phase III RCTs and an existing international regulatory precedent (inhaled formulation approved in the US/EU).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Schizophrenia (per literature; not documented in local market licenses — drug not currently marketed in Norway) |
| Predicted New Indication | Manic bipolar affective disorder (acute agitation) |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L1 (≥2 completed Phase 3 RCTs identified in supporting literature) |
| Norway Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available from DrugBank (data gap). Based on information embedded in the supporting literature, loxapine is a first-generation antipsychotic of the dibenzoxazepine class, originally used for schizophrenia treatment in oral form for over three decades. A reformulated inhaled powder (marketed elsewhere as Adasuve®) using the Staccato® thermal aerosol delivery system was subsequently developed, reaching peak plasma concentrations within a median of ~2 minutes — enabling rapid onset of antipsychotic/calming effect.
Schizophrenia and bipolar mania are both severe psychiatric disorders that share an overlapping clinical presentation: acute psychomotor agitation, excessive motor/verbal activity, and risk of escalation to aggression. Because loxapine's antipsychotic action (dopamine D2 / serotonin 5-HT2A receptor antagonism, typical of this drug class) targets these transdiagnostic symptom domains rather than a disease-specific pathology, its efficacy is not necessarily confined to schizophrenia.
This mechanistic plausibility is directly reflected in the literature itself: inhaled loxapine was studied and approved (US FDA/EU) specifically for "acute treatment of agitation associated with schizophrenia or bipolar I disorder" as a single combined indication, and clinical guidelines for bipolar mania (Pacchiarotti et al. 2020) list antipsychotics such as loxapine among recommended pharmacologic options — supporting the TxGNN-predicted association rather than representing a novel or speculative hypothesis.
Clinical Trial Evidence
Currently no related clinical trials registered (no structured entries present in clinical_trials or ictrp_trials). Note: several literature items below reference completed Phase III RCTs (e.g., NCT00628589, NCT00721955 per Zeller et al. 2017) that were not captured as structured trial registry entries in this evidence pack.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 29724638 | 2018 | RCT | Eur Neuropsychopharmacol | PLACID study: assessor-blind RCT (23 centres, 4 countries) comparing inhaled loxapine vs IM aripiprazole for acute agitation in schizophrenia/bipolar I disorder |
| 29163985 | 2017 | RCT (post-hoc analysis) | BJPsych Open | Responder analysis of 2 completed Phase III RCTs (NCT00628589, NCT00721955; 344 schizophrenia + 314 bipolar I patients) using PANSS-EC scale |
| 22226343 | 2012 | RCT (secondary analysis) | Int J Clin Pract | Effect-size analysis from 2 Phase III RCTs of inhaled loxapine in schizophrenia/bipolar disorder agitation |
| 27151529 | 2016 | Systematic Review & Meta-analysis | Hum Psychopharmacol | Systematic review of short-term pharmacologic interventions for agitation in schizophrenia/bipolar disorder |
| 28376877 | 2017 | RCT Protocol | BMC Psychiatry | Design of PLACID RCT comparing inhaled loxapine vs IM aripiprazole in acute agitation |
| 33460070 | 2020 | Review | Acta Psychiatr Scand | Evidence-based treatment options and clinical guidance for bipolar mania, including antipsychotic choice |
| 30721526 | 2019 | Expert Review | Drugs in R&D | Review of inhaled loxapine for acute agitation management in bipolar disorder and schizophrenia |
| 23740380 | 2013 | Review | CNS Drugs | Review of loxapine inhalation powder (Adasuve®) pharmacokinetics and Phase III trial data |
| 28208695 | 2017 | Clinical Review | Int J Mol Sci | Narrative/clinical mini-review of inhaled loxapine efficacy and tolerability in acute agitation |
| 37581475 | 2023 | Review | Expert Opin Pharmacother | Review of pharmacotherapy options for agitation associated with bipolar disorder |
Norway Market Information
Not currently marketed in Norway — no authorization records available (total_licenses: 0).
Safety Considerations
Local package insert data (warnings, contraindications, drug-drug interactions) is currently unavailable — this has been flagged as a Blocking data gap (DG001), meaning the candidate cannot yet enter formal safety pre-assessment (S1 stage). Please refer to the package insert for safety information once obtained.
Conclusion and Next Steps
Decision: Hold
Rationale: Literature evidence is strong (L1: ≥2 completed Phase III RCTs, one dedicated head-to-head RCT, and a systematic review/meta-analysis), and the predicted indication is corroborated by an existing international regulatory precedent (inhaled loxapine approved in the US/EU for agitation in schizophrenia or bipolar I disorder). However, the candidate cannot proceed past initial safety screening because local warnings/contraindications data is completely unavailable (Blocking gap DG001), and the drug is not currently marketed in Norway.
To proceed, the following is needed:
- Retrieve official label/package insert safety data (warnings, contraindications) — source: TFDA-equivalent regulatory filing or EMA/FDA label
- Obtain detailed MOA/pharmacology data from DrugBank (DG002)
- Confirm intended route of administration (oral vs. inhaled Staccato® delivery) and its regulatory pathway in Norway
- Conduct DDI screening (currently
query_status: not_found)Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.